Price T Rowe Associates Inc. MD Has $183.05 Million Holdings in Biohaven Ltd. (NYSE:BHVN)

Price T Rowe Associates Inc. MD boosted its holdings in shares of Biohaven Ltd. (NYSE:BHVN) by 6.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,347,022 shares of the company’s stock after acquiring an additional 212,699 shares during the period. Price T Rowe Associates Inc. MD’s holdings in Biohaven were worth $183,050,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Thompson Davis & CO. Inc. acquired a new stake in shares of Biohaven during the fourth quarter worth $214,000. Prevail Innovative Wealth Advisors LLC bought a new position in shares of Biohaven during the fourth quarter worth about $230,000. Private Advisor Group LLC bought a new stake in shares of Biohaven in the fourth quarter worth $231,000. Capstone Investment Advisors LLC acquired a new position in Biohaven during the fourth quarter worth $235,000. Finally, Cypress Wealth Services LLC bought a new position in Biohaven in the first quarter valued at $326,000. 88.78% of the stock is owned by institutional investors and hedge funds.

Biohaven Stock Performance

Shares of NYSE:BHVN traded down $1.15 on Monday, reaching $40.06. 294,699 shares of the company’s stock were exchanged, compared to its average volume of 1,238,994. Biohaven Ltd. has a twelve month low of $16.45 and a twelve month high of $62.21. The company has a fifty day moving average of $35.57 and a 200-day moving average of $43.33.

Biohaven (NYSE:BHVN) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($2.20) EPS for the quarter, missing analysts’ consensus estimates of ($1.50) by ($0.70). Equities research analysts predict that Biohaven Ltd. will post -7.09 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director John W. Childs purchased 28,000 shares of the business’s stock in a transaction dated Thursday, May 30th. The stock was bought at an average price of $35.58 per share, with a total value of $996,240.00. Following the acquisition, the director now owns 2,311,341 shares in the company, valued at approximately $82,237,512.78. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Biohaven news, Director John W. Childs bought 28,400 shares of the firm’s stock in a transaction on Thursday, July 18th. The shares were purchased at an average price of $35.67 per share, for a total transaction of $1,013,028.00. Following the completion of the transaction, the director now directly owns 2,339,741 shares in the company, valued at approximately $83,458,561.47. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director John W. Childs acquired 28,000 shares of the company’s stock in a transaction that occurred on Thursday, May 30th. The stock was bought at an average cost of $35.58 per share, with a total value of $996,240.00. Following the purchase, the director now owns 2,311,341 shares in the company, valued at $82,237,512.78. The disclosure for this purchase can be found here. Insiders have bought 84,900 shares of company stock worth $3,011,613 over the last ninety days. Corporate insiders own 16.00% of the company’s stock.

Analyst Upgrades and Downgrades

BHVN has been the topic of several analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Biohaven in a research report on Thursday, May 30th. Morgan Stanley initiated coverage on Biohaven in a research note on Wednesday, July 24th. They issued an “overweight” rating and a $58.00 price target for the company. UBS Group upped their price objective on Biohaven from $59.00 to $60.00 and gave the stock a “buy” rating in a research note on Tuesday, April 23rd. Royal Bank of Canada reissued an “outperform” rating and issued a $59.00 target price on shares of Biohaven in a research note on Tuesday, June 18th. Finally, HC Wainwright restated a “buy” rating and set a $59.00 target price on shares of Biohaven in a report on Thursday, May 30th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $55.13.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.